$36.42
1.48% yesterday
Nasdaq, Apr 29, 10:18 pm CET
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

BridgeBio Pharma Inc Stock price

$36.42
+1.85 5.35% 1M
+11.92 48.65% 6M
+8.98 32.73% YTD
+10.95 42.99% 1Y
+28.40 354.11% 3Y
+4.64 14.60% 5Y
+8.87 32.20% 10Y
Nasdaq, Closing price Tue, Apr 29 2025
+0.53 1.48%
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

Key metrics

Market capitalization $6.91b
Enterprise Value $8.45b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 38.10
P/S ratio (TTM) P/S ratio 31.16
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2,285.27%
Revenue (TTM) Revenue $221.90m
EBIT (operating result TTM) EBIT $-577.37m
Free Cash Flow (TTM) Free Cash Flow $-521.66m
Cash position $681.23m
EPS (TTM) EPS $-2.85
P/E forward negative
P/S forward 28.94
EV/Sales forward 35.38
Short interest 17.95%
Show more

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a BridgeBio Pharma Inc forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
84%
Hold
16%

Financial data from BridgeBio Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
222 222
2,286% 2,286%
100%
- Direct Costs 8.45 8.45
14% 14%
4%
213 213
11,376% 11,376%
96%
- Selling and Administrative Expenses 278 278
100% 100%
125%
- Research and Development Expense 506 506
11% 11%
228%
-571 -571
4% 4%
-257%
- Depreciation and Amortization 6.08 6.08
6% 6%
3%
EBIT (Operating Income) EBIT -577 -577
4% 4%
-260%
Net Profit -536 -536
17% 17%
-241%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Neutral
Seeking Alpha
about 7 hours ago
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Chinmay Shukla – Vice President-Strategic Finance Neil Kumar – Chief Executive Officer Matt Outten – Chief Commercial Officer Tom Trimarchi – President and Chief Financial Officer Ananth Sridhar – Chief Operating Officer-BridgeBio Cardiorenal Conference Call Participants Salim S...
Neutral
GlobeNewsWire
about 13 hours ago
- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers
Neutral
GlobeNewsWire
2 days ago
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Neil Kumar
Employees 730
Founded 2015
Website www.bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today